GlassScriptPhysician profile
Varun Saxena
NPI 1922072784
$5,761.23
in general payments reported to CMS, 2019-2025
24 companies · $669 in 2025
The $669 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $679 · 2020: $703 · 2021: $1,202 · 2022: $1,073 · 2023: $694 · 2024: $743 · 2025: $669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,105.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $761.62 | 2021-2025 | Verquvo, Capvaxive |
| Novartis Pharmaceuticals Corporation | $714.35 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $653.20 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $606.07 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $577.82 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $547.02 | 2020-2025 | Jardiance |
| Amgen INC. | $375.63 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $313.59 | 2019-2024 | Watchman Access System, Bodyguardian |
| Astrazeneca Pharmaceuticals LP | $241.69 | 2019-2024 | Farxiga |
| Amarin Pharma, INC. | $223.07 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $149.31 | 2019-2024 | |
| Novo Nordisk INC | $126.80 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lundbeck LLC | $120.04 | 2019-2021 | |
| Scpharmaceuticals INC. | $51.69 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $51.63 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $51.19 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $49.53 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $31.88 | 2025 | |
| Gilead Sciences, INC. | $28.10 | 2019 | |
| Medicomp INC | $19.51 | 2024 | Telepatch Cardiac Monitor |
| Abiomed | $18.11 | 2019 | |
| Biotronik INC. | $17.79 | 2025 | Biomonitor |
| Philips North America LLC | $17.04 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Varun Saxena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.